US FDA wants more data on once-monthly Invega
This article was originally published in Scrip
Executive Summary
The US FDAhas asked Johnson & Johnsonin a complete response letter to provide additional information on paliperidone palmitate, its investigational once-monthly formulation of Invega (paliperidone), for treating schizophrenia and preventing recurrence of symptoms.